NGM Biopharmaceuticals Inc (NGM) Share Price

NGM under $2

NGM under $2

NGM...NICE CLOSE AND MORE TO COME PUSHING UP AND UNDER THAT WEEKLY CLOUD!!!!

NGM...1.86 PIVOT BREAK...LITTLE BIO BEAST!!

NGM....READY AGAIN...1.86 PIVOT!

NGM...HERE WE GO BREAKING 1.73....2.39 PIVOT UP A HEAD

NGM..NEXT STOP 1.73

NGM..HERE WE GO

NGM...THIS ONE WILL SHOCK THE BIO SCENE

NGM...MONSTER IN THE MAKING

WATCH AND LEARN...1.45 BREAK AND WE ARE OFF

Bionic quicksand just around the corner..

NGM Taking a stab here. Dangerous play

$1.21 +0https://investorshub.advfn.com/boards/edit_msg.aspx?message_id=173543744.351 (+40.86%)

https://stockcharts.com/h-sc/ui?s=NGM

Ngm Biopharmaceuticals Confirmed It Received A Non-Binding Expression Of Interest From The Column Group Regarding Potential Acquisition Of All Outstanding Shares Of Common Stock Of The Company Not Already Owned By TCG In A Going-Private Transaction
BENZINGA
7:36 AM ET Jan-02-2024
NGM Biopharmaceuticals, Inc. (NGM.NaE) today confirmed that it has received a non-bindingexpression of interest dated December 28, 2023 (the "EOI") from The Column Group,
NGM Biopharmaceuticals, Inc. (NGM.NaE) today confirmed that it has received a non-bindingexpression of interest dated December 28, 2023 (the "EOI") from The Column Group, LP and certain affiliated investment funds and persons (collectively, "TCG"), outlining TCG's intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by TCG in a going-private transaction. TCG currently beneficially owns approximately 26.7% of the outstanding shares of NGM Bio's common stock. A copy of the EOI is attached to TCG's amended Schedule 13D filed with the Securities and Exchange Commission on December 29, 2023.

In response to the EOI, the Company's Board of Directors has formed a special committee consisting of disinterested and independent directors to consider the EOI and any other strategic alternatives that may be available to the Company, including remaining a standalone publicly-traded company. The special committee has retained Hogan Lovells US LLP as its independent legal advisor, and intends to retain an independent financial advisor, to assist it in considering the EOI. Cooley LLP is acting as legal advisor to the Company.

NGM...BIO BEAST SEES A 1.84 EXIT INTO BIOVILLE

NGM...MASSIVE BIO BEAST VOLUME

NGM...BIO BOTTOM BEAST READY TO BEAST THROUGH BIOVILLE

NGM new 52 week low

NGM under $2